2024
Phase II Trial of Reduced-Intensity Fludarabine, Melphalan 70 Mg/m2, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant
Elmariah H, Kim J, DiMaggio E, Gonzalez R, Kim J, Kim J, Mishra A, Faramand R, Perez L, Lazaryan A, Khimani F, Liu H, Ochoa L, Nieder M, Figura N, Robinson T, Nishihori T, Anasetti C, Pidala J, Bejanyan N. Phase II Trial of Reduced-Intensity Fludarabine, Melphalan 70 Mg/m2, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant. Transplantation And Cellular Therapy 2024, 30: s58-s59. DOI: 10.1016/j.jtct.2023.12.093.Peer-Reviewed Original ResearchDisease-free survivalNon-relapse mortalityPost-transplant cyclophosphamidePhase II trialHaplo-PBSCTHematopoietic cell transplantationRate of relapseCumulative incidenceHCT-CIPrimary endpointCumulative incidence of grade II–IV acute GVHDCumulative incidence of non-relapse mortalityIncidence of grade II-IV acute GVHDGrade II-IV acute GVHDGVHD-free relapse-free survivalIncidence of non-relapse mortalityModerate to severe chronic GVHDHematopoietic cell transplantation comorbidity indexMedian follow-up timeChronic GVHD ratesGraft failure eventsHCT-CI scoreSevere chronic GVHDRelapse-free survivalRisk of relapse
2023
Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant
Elmariah H, Kim J, Mishra A, Faramand R, Perez L, Lazaryan A, Khimani F, Liu H, Ochoa-Bayona J, Nieder M, Figura N, Robinson T, Nishihori T, Anasetti C, Pidala J, Bejanyan N. Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant. Blood 2023, 142: 4900. DOI: 10.1182/blood-2023-187473.Peer-Reviewed Original ResearchDisease-free survivalPost-transplant cyclophosphamideHematopoietic cell transplantNon-relapse mortalityPhase II trialTotal body irradiationAllogeneic hematopoietic cell transplantReduced-intensity conditioningBone marrow graftsPrimary endpointII trialCumulative incidenceGVHD prophylaxisCell transplantHematologic malignanciesCyclophosphamide/total body irradiationGVHD-free relapse-free survivalHematopoietic cell transplant comorbidity indexPeripheral blood stem cell graftsSingle-center phase II trialPeripheral blood stem cell transplantBlood stem cell graftsHigh-risk hematologic malignanciesMonths disease free survivalDay 6